(Adnkronos) - “Oggi In Italia abbiamo più di 800mila pazienti con questo tumore, e 55mila nuove diagnosi l’anno. Grazie a ricerca importante miglioramento in quantità e qualità di vita. Obiettivo principale Novartis trovare opzioni terapeutiche sempre più innovative, con più di 320 studi clinici l’anno che permettono il trattamento di più di 2.000 pazienti”.
Category
🗞
NewsTranscript
00:00Novartis is committed for more than 30 years in the care of the mammary carcinoma.
00:12The mammary carcinoma certainly represents a pathology with a great impact on the oncological pathology.
00:22Today, in Italy, we have more than 800,000 patients with about 55,000 new cases every year.
00:36The commitment of Novartis in the field of clinical research has led to an important improvement
00:44both in terms of quantity of life and in terms of quality of life of patients affected by the mammary carcinoma.
00:52Today, our commitment is based on the possibility of bringing treatments in earlier stages
01:00in order to try to eliminate as much as possible the risk of recidivism.
01:07The main goal, of course, is to try to find increasingly innovative therapeutic solutions.
01:14Novartis is committed in the field of clinical research with more than 240 clinical studies every year
01:22that allow the treatment of more than 2,000 patients.
01:26Obviously, this alone is not enough.
01:31An active collaboration with all stakeholders of the health system is necessary,
01:36in particular with patient associations, clinical associations and institutions
01:42in order to investigate more and more the unmet needs of patients
01:49in order to go more and more towards a personalization of the treatment
01:55and towards the possibility of ensuring that these treatments can then actually reach the patient's bed
02:04also through partnerships with associations and institutions that allow more and more equal access to treatments.